Cooling inflammation while potentiating immune checkpoint inhibition: Enhancing the benefit-risk ratio of immuno-oncology therapy

Proc Natl Acad Sci U S A. 2024 Feb 27;121(9):e2400431121. doi: 10.1073/pnas.2400431121. Epub 2024 Feb 14.

Authors

David A Potter^{1

2}, Zhijun Guo¹, Jianxun Lei¹, Emmanuel S Antonarakis^{1

2}

Affiliations

¹ Department of Medicine, Division of Hematology, Oncology, and Transplantation and Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455.
² Masonic Cancer Center, Minneapolis, MN 55455.

PMID: 38354255
PMCID: PMC10907316 (available on 2024-08-14)
DOI: 10.1073/pnas.2400431121

No abstract available

Publication types

Comment

MeSH terms

Epoxide Hydrolases
Humans
Immune Checkpoint Inhibitors* / therapeutic use
Immunotherapy
Neoplasms* / drug therapy
Neoplasms* / immunology
Odds Ratio

Substances

Immune Checkpoint Inhibitors
Epoxide Hydrolases

Grants and funding

P30 CA077598/CA/NCI NIH HHS/United States